No Data
No Data
No Data
No Data
No Data
Hoth Therapeutics Stockholders to Sell Up to 5.03M Shrs
Hoth Therapeutics Stockholders to Sell Up to 5.03M Shrs
Dow JonesApr 12 04:23
Promising Preclinical Alzheimer's Candidate and Diverse Pipeline Bolster Hoth Therapeutics' Buy Rating
TipRanksApr 5 18:26
Hoth Therapeutics Price Target Maintained With a $4.00/Share by HC Wainwright & Co.
Hoth Therapeutics Price Target Maintained With a $4.00/Share by HC Wainwright & Co.
Dow JonesApr 5 18:25
HC Wainwright & Co. Reiterates Buy on Hoth Therapeutics, Maintains $4 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Hoth Therapeutics with a Buy and maintains $4 price target.
Analyst UpgradesApr 5 18:15
Hoth Therapeutics Is Maintained at Buy by EF Hutton
Hoth Therapeutics Is Maintained at Buy by EF Hutton
Dow JonesApr 2 21:13
EF Hutton Maintains Buy on Hoth Therapeutics, Raises Price Target to $7
EF Hutton analyst Tim Moore maintains Hoth Therapeutics with a Buy and raises the price target from $6.5 to $7.
Analyst UpgradesApr 2 21:03
No Data
No Data